Spyre Financial Statements From 2010 to 2026

SYRE Stock

33.24 0.15 0.45%

Spyre Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Spyre Therapeutics' valuation are provided below:

Gross Profit

-177.5 M

Quarterly Earnings Growth

(1.00)

Market Capitalization

2.6 B

Enterprise Value Revenue

2 K

Earnings Share

(1.32)

There are over one hundred nineteen available fundamental trend indicators for Spyre Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to double-check all of Spyre Therapeutics' current performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 1 B. The current year's Enterprise Value is expected to grow to about 950.1 M

Spyre Therapeutics Total Revenue

757,530

Check Spyre Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spyre Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 855.5 K, Gross Profit of 757.5 K or Other Operating Expenses of 251.8 M, as well as many indicators such as Price To Sales Ratio of 158, Dividend Yield of 0.0 or PTB Ratio of 2.31. Spyre financial statements analysis is a perfect complement when working with Spyre Therapeutics Valuation or Volatility modules.

Build AI portfolio with Spyre Stock

Check out the analysis of Spyre Therapeutics Correlation against competitors.

For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.

Spyre Therapeutics Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

734.7 M

699.8 M

180.7 M

Slightly volatile

Other Current Liabilities

64.5 M

61.4 M

16.4 M

Slightly volatile

Total Current Liabilities

65.3 M

62.2 M

18.4 M

Slightly volatile

Total Stockholder Equity

625.2 M

595.5 M

146.4 M

Slightly volatile

Accounts Payable

1.2 M

765.9 K

913.3 K

Slightly volatile

Cash

108 M

102.8 M

46 M

Slightly volatile

Cash And Short Term Investments

728.2 M

693.6 M

174.9 M

Slightly volatile

Liabilities And Stockholders Equity

734.7 M

699.8 M

180.7 M

Slightly volatile

Total Liabilities

109.5 M

104.3 M

34.3 M

Slightly volatile

Total Current Assets

734.7 M

699.7 M

178.1 M

Slightly volatile

Common Stock

11.1 K

11.7 K

208.1 K

Slightly volatile

Non Current Assets Total

10.9 K

11.5 K

2.6 M

Pretty Stable

Non Currrent Assets Other

10.9 K

11.5 K

130.8 K

Pretty Stable

Common Stock Shares Outstanding

56.8 M

54.1 M

10.5 M

Slightly volatile

Other Current Assets

3.4 M

6.2 M

2.6 M

Slightly volatile

Net Receivables

320.6 K

337.5 K

1.1 M

Slightly volatile

Short Term Investments

620.3 M

590.7 M

130 M

Slightly volatile

Non Current Liabilities Total

44.2 M

42.1 M

16 M

Slightly volatile

Other Stockholder Equity

1.6 B

1.5 B

425.8 M

Slightly volatile

Current Deferred Revenue

564.8 K

594.5 K

2.7 M

Pretty Stable

Other Assets

0.8

0.9

0.9824

Slightly volatile

Short and Long Term Debt Total

102.1 M

97.2 M

25.6 M

Slightly volatile

Capital Stock

188.2 M

179.2 M

41.7 M

Slightly volatile

Non Current Liabilities Other

44.2 M

42.1 M

12.1 M

Slightly volatile

Net Working Capital

669.5 M

637.6 M

176 M

Slightly volatile

Short Term Debt

483.7 K

718.8 K

448.4 K

Slightly volatile

Spyre Therapeutics Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

855.5 K

1.1 M

623.2 K

Slightly volatile

Other Operating Expenses

251.8 M

239.9 M

85.1 M

Slightly volatile

Research Development

196.6 M

187.2 M

58.8 M

Slightly volatile

Cost Of Revenue

1.2 M

1.1 M

799.2 K

Slightly volatile

Total Operating Expenses

251.8 M

239.9 M

85 M

Slightly volatile

Selling General Administrative

29.4 M

52.6 M

20.7 M

Slightly volatile

Net Interest Income

25.7 M

24.5 M

5.5 M

Slightly volatile

Interest Income

25.7 M

24.5 M

5.5 M

Slightly volatile

Spyre Therapeutics Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Stock Based Compensation

54.1 M

51.6 M

13 M

Slightly volatile

Begin Period Cash Flow

228.5 M

217.6 M

55.3 M

Slightly volatile

Depreciation

731 K

855.6 K

527.8 K

Slightly volatile

Other Non Cash Items

11.3 M

11.9 M

16.4 M

Slightly volatile

Total Cash From Financing Activities

496.2 M

472.5 M

129 M

Slightly volatile

End Period Cash Flow

55.8 M

102.8 M

42.8 M

Slightly volatile

Other Cashflows From Financing Activities

210.7 M

200.7 M

46.3 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

158

151

52.0915

Slightly volatile

PTB Ratio

2.31

2.43

22.5815

Slightly volatile

Days Sales Outstanding

107

67.59

78.6588

Slightly volatile

Book Value Per Share

12.03

12.66

37.8065

Very volatile

Stock Based Compensation To Revenue

27.38

26.08

6.9294

Slightly volatile

Capex To Depreciation

0.0265

0.0279

3.6438

Slightly volatile

PB Ratio

2.31

2.43

22.5815

Slightly volatile

Payables Turnover

0.68

0.65

0.3904

Slightly volatile

Sales General And Administrative To Revenue

42.61

40.58

11.7778

Slightly volatile

Research And Ddevelopement To Revenue

95.46

90.92

26.5735

Slightly volatile

Capex To Revenue

0.0178

0.0188

0.0386

Pretty Stable

Cash Per Share

14.01

14.75

41.0861

Very volatile

Days Payables Outstanding

553

583

2.5 K

Slightly volatile

Income Quality

0.88

0.87

0.7862

Pretty Stable

Net Debt To EBITDA

0.97

0.49

0.7163

Very volatile

Current Ratio

6.62

10.13

7.3999

Slightly volatile

Tangible Book Value Per Share

12.03

12.66

37.8065

Very volatile

Receivables Turnover

6.13

5.59

8.7845

Slightly volatile

Shareholders Equity Per Share

12.03

12.66

37.8065

Very volatile

Debt To Equity

0.0551

0.0828

0.0798

Pretty Stable

Capex Per Share

0.0096

0.0101

0.4484

Pretty Stable

Graham Net Net

11.9

12.53

34.5086

Very volatile

Revenue Per Share

0.14

0.15

7.5034

Slightly volatile

Interest Debt Per Share

2.7

1.58

3.0878

Slightly volatile

Debt To Assets

0.0411

0.0586

0.0578

Slightly volatile

Operating Cycle

107

67.59

78.6588

Slightly volatile

Price Book Value Ratio

2.31

2.43

22.5815

Slightly volatile

Days Of Payables Outstanding

553

583

2.5 K

Slightly volatile

Ebt Per Ebit

0.83

0.9

1.0495

Slightly volatile

Company Equity Multiplier

1.05

1.06

1.3028

Pretty Stable

Total Debt To Capitalization

0.0513

0.0758

0.0736

Pretty Stable

Debt Equity Ratio

0.0551

0.0828

0.0798

Pretty Stable

Quick Ratio

6.62

10.13

7.3999

Slightly volatile

Net Income Per E B T

1.1

1.15

1.0161

Slightly volatile

Cash Ratio

1.81

1.9

3.797

Pretty Stable

Days Of Sales Outstanding

107

67.59

78.6588

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

1.12

1.15

1.0325

Slightly volatile

Price To Book Ratio

2.31

2.43

22.5815

Slightly volatile

Fixed Asset Turnover

0.38

0.4

7.7125

Slightly volatile

Debt Ratio

0.0411

0.0586

0.0578

Slightly volatile

Price Sales Ratio

158

151

52.0915

Slightly volatile

Asset Turnover

0.0028

0.003

0.1007

Slightly volatile

Price Fair Value

2.31

2.43

22.5815

Slightly volatile

Spyre Therapeutics Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

1 B

985.3 M

308.2 M

Slightly volatile

Spyre Fundamental Market Drivers

Spyre Upcoming Events

	7th of March 2024 Upcoming Quarterly Report	View
	9th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	7th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Spyre Therapeutics Financial Statements

Spyre Therapeutics stakeholders use historical fundamental indicators, such as Spyre Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Spyre Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Spyre Therapeutics' assets and liabilities are reflected in the revenues and expenses on Spyre Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Spyre Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Current Deferred Revenue	594.5 K	564.8 K
Cost Of Revenue	1.1 M	1.2 M
Total Revenue	797.4 K	757.5 K
Stock Based Compensation To Revenue	26.08	27.38
Sales General And Administrative To Revenue	40.58	42.61
Research And Ddevelopement To Revenue	90.92	95.46
Capex To Revenue	0.02	0.02
Revenue Per Share	0.15	0.14
Ebit Per Revenue	(314.50)	(298.78)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

GOOG	Alphabet Inc Class C
V	Visa Class A
MSFT	Microsoft

When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:

How To Invest In Spyre

Details

Is Spyre Stock a good investment?

Details

What is Spyre Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Spyre Therapeutics Correlation against competitors.

For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.

You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(1.00)

Earnings Share

(1.32)

Return On Assets

(0.30)

Return On Equity

(0.38)

The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Spyre Financial Statements From 2010 to 2026

Spyre Therapeutics Total Revenue

757,530

Spyre Therapeutics Balance Sheet

Spyre Therapeutics Income Statement

Spyre Therapeutics Cash Flow Statement

Financial Ratios

Spyre Therapeutics Valuation Data

Spyre Fundamental Market Drivers

Spyre Upcoming Events

About Spyre Therapeutics Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY